Norspan (Buprenorphine)

Buprenorphine, the active ingredient in Norspan, is an opioid analgesic presented as a 5‑20 µg/h transdermal patch for transdermal use. It treats severe chronic pain and cancer‑related pain in adult patients.

GNH USA supplies Norspan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Buprenorphine is an opioid analgesic used for managing pain conditions that require continuous opioid therapy. - Severe chronic pain: provides steady analgesia for patients with persistent non‑cancer pain. - Cancer pain: controls pain associated with malignant disease. - Opioid rotation: can be employed when switching from other opioid regimens to maintain analgesic control.

Adverse reactions may occur with Norspan transdermal patches.

Common Side Effects: - Application site erythema or itching. - Nausea. - Constipation. - Dizziness.

Serious or Rare Side Effects: - Respiratory depression. - Severe hypotension. - Opioid dependence or withdrawal. - Life‑threatening skin reactions such as Stevens‑Johnson syndrome.

Before prescribing Norspan, clinicians should consider several safety measures. - Assess opioid tolerance: confirm patient has prior opioid exposure. - Monitor respiratory function: watch for signs of depression, especially in the first 24 hours. - Avoid use in severe respiratory disease: patients with COPD or sleep apnea are at higher risk. - Use caution in hepatic impairment: dose adjustments may be required. - Do not discontinue abruptly: taper to prevent withdrawal. - Store at room temperature: keep patches in the original packaging, protect from moisture and direct sunlight.

Buprenorphine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, alcohol): additive respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase buprenorphine levels. - MAO inhibitors: risk of hypertensive crisis. - Concurrent opioids: heightened risk of overdose.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Certain antidepressants (e.g., SSRIs): may increase sedation. - Diuretics: monitor blood pressure and electrolytes.